"10.1371_journal.pone.0132142","plos one","2015-07-01T00:00:00Z","Virginie Dutoit-Lefèvre; Sylvain Dubucquoi; David Launay; Vincent Sobanski; Patricia Dussart; Philippe Chafey; Cédric Broussard; Sophie Duban-Deweer; Patrick Vermersch; Lionel Prin; Didier Lefranc","Institut dImmunologie, Centre de Biologie Pathologie et Génétique, Centre Hospitalier Régional Universitaire, Lille, France; UMR 995, LIRIC, INSERM, Lille, France; EA 2686, Univ Lille Nord de France, Lille, France; Service de Médecine Interne et dImmunologie clinique, Centre National de Référence Maladies rares, Centre Hospitalier Régional Universitaire, Lille, France; INSERM U1016, Institut Cochin, Paris, France; UMR 8104, CNRS Paris, France; Plate-forme Protéomique 3P5, Univ Paris Descartes, Sorbonne Paris Cité, Paris, France; LBHE, EA 2465, UArtois, Lens, France; Service de Neurologie D, Centre Hospitalier Régional Universitaire, Lille, France","Conceived and designed the experiments: VDL SD DLa DLe. Performed the experiments: VDL VS PD CB SDD DLe. Analyzed the data: VDL VS SD DLa CB DLe. Contributed reagents/materials/analysis tools: VDL PD PC CB SDD DLe. Wrote the paper: VDL SD DLa PD PC CB SDD PV LP DLe.","Pfizer and Merck Serono provided funding towards this study. There are no patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2015","07","Virginie Dutoit-Lefèvre","VDL",11,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
